- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02715570
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945
April 30, 2018 updated by: Pulmocide Ltd
A Randomised, Single-blind, Placebo-controlled, Study to Assess the Safety and Tolerability of Single Escalating and Repeat, Inhaled Doses of PC945 in Healthy Subjects Combined With a Randomised, Single-blind, Placebo-controlled, Parallel Group to Assess the Safety and Tolerability of a Single Dose of Inhaled PC945 in Subjects With Mild Asthma
PC945 is a new medicine being developed for treatment of fungal lung diseases.
The main purpose of this study is to investigate the safety, tolerability and pharmacokinetics of single and repeat doses of PC945
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
29
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Middlesex
-
Harrow, Middlesex, United Kingdom, HA1 3UJ
- Parexel Epcu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
All subjects (Cohorts 1, 2 & 3)
- Male or female, aged between 18 and 65 years inclusive (at the time of consent) who fit one of the following criteria: Women of childbearing potential who are willing and able to use required contraception from screening until 30 days after receipt of the final dose; Women of non-childbearing potential defined as being amenorrhoeic or have been permanently sterilised; Men who are willing and able to use required contraception from the time of the first dose, until 90 days after receipt of the final dose of study medication.
- Females with a negative pregnancy test at screening and at Day -1.
- Willing and able to adhere to the restrictions and prohibitions required by this protocol.
- Signed informed consent form.
- Body weight ≥ 50 kg and body mass index (BMI) within the range 18 - 30 kg/m2 (inclusive).
- Average QTcF <450 msec at screening and pre-dose.
- Vital signs assessments within normal ranges
Healthy Subjects (Cohorts 1 and 2)
- Healthy as determined by a physician based on a full medical examination.
- Spirometry readings (FEV1 and FVC) to be ≥ 80% of predicted value and FEV1/FVC ratio > 0.7 at screening.
Subjects with Asthma (Cohort 3)
- Diagnosis of asthma.
- Positive result to methacholine challenge at the screening visit.
- FEV1 >60% of predicted normal value at screening.
- Stable asthma based on physician assessment at screening, with no changes of therapy in the 12 weeks prior to screening and no hospitalization or visit to accident and emergency for asthma in the 12 months prior to screening
- Otherwise healthy on the basis of a full medical examination at screening
Exclusion Criteria:
All subjects (Cohorts 1, 2 & 3)
- Any acute illness.
- Upper or lower respiratory tract infection within 4 weeks of the screening visit or randomisation.
- Use of prescription medications within 14 days of the Screening visit.
- Taking over the counter (OTC) medications other than vitamins or multivitamins, within 14 days prior to Screening.
- History of regular alcohol consumption within 6 months of the study with average weekly intake of >21 units for males, or >14 units for females.
- History of drug or alcohol abuse within the previous 5 years.
- Smoker (regular or irregular), or has smoked or used nicotine-containing products (including e-cigarettes) within the 6 months prior to screening or has a smoking history of ≥ 10 pack years.
- Positive test for HIV-1 & -2 antibodies at screening.
- Positive pre-study hepatitis B surface antigen or positive hepatitis C antibody result at screening.
- Positive test for alcohol, smoking or drugs of abuse at screening or Day -1.
- Received an experimental drug or used an experimental medical device within last 3 months.
- Allergy to any of the active or inactive ingredients in the study medication.
- Donation of blood in excess of 500 mL within a 3 month period prior to dosing, or if study participation would result in blood loss in excess of 500 mL in a 3 month period.
- Mentally or legally incapacitated.
- An employee of the Sponsor or contract research organisation (CRO), or a relative of an employee of the Sponsor or CRO.
- Unable or unwilling to undergo multiple venepuncture procedures or poor access to veins suitable for cannulation.
- Pregnant or lactating female
Healthy subjects (Cohorts 1 and 2)
- Any chronic illness or clinically relevant abnormality identified on the screening medical assessment, laboratory tests or ECG.
Subjects with asthma (Cohort 3)
- Had an episode of life-threatening asthma.
- Presence of clinically significant diseases other than asthma, hyper-responsive airways, seasonal allergic rhinitis or atopic diseases.
- Experienced an acute asthma exacerbation in the 12 months prior to screening requiring hospitalisation or accident and emergency treatment or management with systemic or injectable steroids.
- Uncontrolled, or moderate to severe asthma based on PI assessment and/or use of prohibited medications, or has required treatment with these therapies in the previous 12 weeks.
- History or presence of any known conditions contraindicated for methacholine challenge.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single dose - healthy volunteers
|
Safety and tolerability of single doses
Safety and tolerability of single doses
|
Experimental: Repeat dose - healthy volunteers
|
Safety and tolerability of repeat doses
Safety and tolerability of repeat doses
|
Experimental: Single dose - asthmatic patients
|
Safety and tolerability of single doses
Safety and tolerability of single doses
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment emergent adverse events
Time Frame: Cohort 1 - 12 weeks; Cohort 2 - 7 weeks; Cohort 3 - 6 weeks
|
Assessment of number of adverse events reported by subjects following dosing
|
Cohort 1 - 12 weeks; Cohort 2 - 7 weeks; Cohort 3 - 6 weeks
|
12-lead ECG assessment
Time Frame: Cohort 1 - 12 weeks; Cohort 2 - 7 weeks; Cohort 3 - 6 weeks
|
Change from pre-dose values
|
Cohort 1 - 12 weeks; Cohort 2 - 7 weeks; Cohort 3 - 6 weeks
|
Vital signs assessment (blood pressure and heart rate - measured together)
Time Frame: Cohort 1 - 12 weeks; Cohort 2 - 7 weeks; Cohort 3 - 6 weeks
|
Change for pre-dose values
|
Cohort 1 - 12 weeks; Cohort 2 - 7 weeks; Cohort 3 - 6 weeks
|
Clinical laboratory assessments (blood and urine samples - measured together)
Time Frame: Cohort 1 - 12 weeks; Cohort 2 - 7 weeks; Cohort 3 - 6 weeks
|
Change from pre-dose values
|
Cohort 1 - 12 weeks; Cohort 2 - 7 weeks; Cohort 3 - 6 weeks
|
Spirometry assessment (FEV1 & FVC - measured together)
Time Frame: Cohort 1 - 12 weeks; Cohort 2 - 7 weeks; Cohort 3 - 6 weeks
|
Change from pre-dose values
|
Cohort 1 - 12 weeks; Cohort 2 - 7 weeks; Cohort 3 - 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma concentration data of PC945
Time Frame: Cohort 1 (4 treatment periods) & Cohort 3 (1 treatment period) Day1 = 8 samples; Day2 = 2 samples; Day3 = 1 sample; F/U = 1 sample. Cohort 2 - Days1&7 = 10 samples; Days2,5,6 = 1 sample; Day8 = 2 samples; Day9 = 1 sample; F/U = 1 sample
|
Blood levels of PC945 measured after dosing
|
Cohort 1 (4 treatment periods) & Cohort 3 (1 treatment period) Day1 = 8 samples; Day2 = 2 samples; Day3 = 1 sample; F/U = 1 sample. Cohort 2 - Days1&7 = 10 samples; Days2,5,6 = 1 sample; Day8 = 2 samples; Day9 = 1 sample; F/U = 1 sample
|
Spirometry assessment (FEV1)
Time Frame: Cohort 3 only - Day 1, 8 hours
|
Observed drops in FEV1 assessment after dosing patients with mild asthma
|
Cohort 3 only - Day 1, 8 hours
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determination of exogenous fungal flora
Time Frame: Cohort 1 (4 treatment periods) & Cohort 3 (1 treatment period) Day1 = 1 sample; Day3 = 1 sample. Cohort 2, Day 1 = 1 sample; Day 9 = 1 sample
|
Assessment of fungal flora found in mouth and throat after dosing
|
Cohort 1 (4 treatment periods) & Cohort 3 (1 treatment period) Day1 = 1 sample; Day3 = 1 sample. Cohort 2, Day 1 = 1 sample; Day 9 = 1 sample
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Muna Albayaty, MBChB, FFPM, MSc, cro
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 23, 2017
Primary Completion (Actual)
April 27, 2018
Study Completion (Actual)
April 27, 2018
Study Registration Dates
First Submitted
March 16, 2016
First Submitted That Met QC Criteria
March 16, 2016
First Posted (Estimate)
March 22, 2016
Study Record Updates
Last Update Posted (Actual)
May 1, 2018
Last Update Submitted That Met QC Criteria
April 30, 2018
Last Verified
April 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PC_ASP_001
- 2015-003327-64 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aspergillosis
-
Imagine InstituteRecruitingInvasive Aspergillosis | Cerebral AspergillosisFrance
-
Astellas Pharma IncWithdrawnAspergillosis/Blood | Aspergillosis/InvasiveUnited States
-
Postgraduate Institute of Medical Education and...RecruitingAllergic Bronchopulmonary Aspergillosis | Chronic Pulmonary AspergillosisIndia
-
University Hospital, MontpellierCompletedSevere Asthma | Allergic Bronchopulmonary Aspergillosis (ABPA)France
-
Shanghai Zhongshan HospitalNot yet recruitingAllergic Bronchopulmonary Aspergillosis
-
Shanghai Pulmonary Hospital, Shanghai, ChinaRecruiting
-
Postgraduate Institute of Medical Education and...Cipla Ltd.CompletedAllergic Bronchopulmonary AspergillosisIndia
-
Radboud University Medical CenterNot yet recruitingPulmonary Aspergillosis | Allergic Bronchopulmonary Aspergillosis | Chronic Pulmonary Aspergillosis
-
Post Graduate Institute of Medical Education and...RecruitingAllergic Bronchopulmonary AspergillosisIndia
-
Postgraduate Institute of Medical Education and...Active, not recruiting
Clinical Trials on PC945 - single doses
-
Novartis PharmaceuticalsCompletedSchizophrenia DisordersUnited States
-
GEN İlaç ve Sağlık Ürünleri A.Ş.Sulfateq B.V.Recruiting
-
EnteromeQuotient ClinicalCompleted
-
Galapagos NVMorphoSys AGCompletedHealthy | Dermatitis, AtopicBelgium, Hungary, Moldova, Republic of, Romania
-
Janssen Research & Development, LLCCompleted
-
MicuRxWorldwide Clinical TrialsCompleted